Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)

Abstract

Vitiligo is an autoimmune disease in which the melanocytes die because of immune cytotoxicity or oxidative stress-induced cell death.1 Repigmentation can be achieved with immunosuppressive therapies, such as topical tacrolimus, topical ruxolitinib, and narrow-band UV therapies. However, the repigmentation often takes a long time, and only a minority of patients achieve satisfactory repigmentation. Therefore, there is a need to expand therapeutic options for this disease.

Topics & Concepts